Phosphatidylinositol 3-kinase (PI3KCA) oncogene mutation analysis and gene expression profiling in primary breast cancer patients

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 9, 2013, Pages 5067-5072

  Kandula, Mahesh ^a   Chennaboina, Kalyan Kumar ^a   Ammi Raju, Y S ^a   Raju, Suryanarayana ^b  

^a Krisani Biosciences Private Limited   (India)

^b NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Breast cancer; Gene expression; Mutations; Phosphatidylinositol 3 kinase

Indexed keywords

MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; BREAST TUMOR; DNA SEQUENCE; EXON; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MIDDLE AGED; MUTATION; PAGET NIPPLE DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL;

EID: 84887579081     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.9.5067     Document Type: Article

References (27)

1. Areumnuri K, Jung EL, Seung SL, et al (2005). Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer. Int J Cancer, 133, 984-96.
2. Bachman KE, Argani P, Samuels Y, et al (2004). The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther, 3, 772-5.
3. Barbareschi MB, Felicioni L, Cotrupi S, et al (2007). Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res, 13, 6064-9.
4. Campbell IG, Russell SE, Choong DY, et al (2004). Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res, 64, 7678-81.
5. Cizkova M, Dujaric ME, Lehmann C, et al (2013). Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. Br J Cancer, 108, 1807-9.
6. Cooper L, Melinda S, Maria G, et al (2013). Clinical and pathologic characteristics of patients with PI3K-mutant breast cancers. J Clin Oncol, 31, 26.
7. Dupont Jensen J, Laenkholm AV, Knoop A, et al (2011). PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res, 4, 667-77.
8. Ihle NT, Lemos R Jr, Wipf P, et al (2009). Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res, 69, 143-50.
9. Kalinsky K, Jacks LM, Heguy A, et al (2009). PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res, 16, 5049-59.
10. Kang S, Bader AG, Vogt PK, et al (2005). Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci, 102, 802-7.
11. Lai YL, Mau BL, Cheng WH, et al (2008). PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol, 4, 1064-9.
12. Lee JW, Soung YH, Kim SY, et al (2005). PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene, 24, 1477-80.
13. Levine DA, Bogomolniy F, Yee CJ, et al (2005). Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res, 11, 2875-8.
14. Li SY, Rong M, Grieu F, et al (2006). PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat, 19, 1-5.
15. Magdalena C, Aurélie S, Sophie V, et al (2012). PIK3CA mutation impact on survival in breast cancer patients and in ERa, PR and ERBB2-based subgroups. Breast Cancer Res, 14, 28.
16. Maruyama N, Miyoshi Y, Taguchi T, et al (2007). Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res, 13, 408-14.
17. Oda K, Okada J, Timmerman L, et al (2008). PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res, 68, 8127-36.
18. Saal LH, Holm K, Maurer M, et al (2005). PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res, 65, 2554-9.
19. Samuels Y, Diaz J, Schmidt-Kittler O, et al (2005). Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell, 7, 561-73.
20. Samuels Y, Ericson K (2006). Oncogenic PI3K and its role in cancer. Curr Opin Oncol, 1, 77-82.
21. Samuels Y, Waldman T (2010). Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol, 347, 21-41.
22. Samuels Y, Wang Z, Bardelli A (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science, 304, 554.
23. Sherene L, Benjamin HK, Samira MF, et al (2010). PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. PNAS, 107, 22.
24. Sherene L, Stefan M, Jose B, et al (2013). PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. J Clin Oncol, 9, 8127-36.
25. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al (2008). An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res, 15, 6084-91.
26. Vivanco I, Sawyers CL (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer, 2, 489-501.
27. Zhao L, Vogt PK (2008). Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA, 105, 2652-7.